Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Recruiting now

Conditions studied: Lung Non-Small Cell Carcinoma

In brief

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Key facts

Study ID

NCT07339254

Run by

University of Southern California

People needed

40

Starts

2026-03-12

Expected to finish

2028-03-12

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• * Age ≥ 18 years.
• * Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
• * Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
• * Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

You may not qualify if…

• * Patients is unable to consent for themselves
• * Patient has not yet completed the 1st cycle of ICI-based therapy

Where it is running

• Los Angeles General Medical Center — Los Angeles, California, United States (enrolling)
• USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.